{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:28:28Z","timestamp":1747225708714,"version":"3.37.3"},"reference-count":37,"publisher":"Consilium Medicum","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Background. Inflammatory bowel diseases (IBD) are characterized by chronic immune inflammation of the mucous membrane and\/or the thickness of the intestinal wall, and are also accompanied by disorders of the blood clotting system and the development of a hypercoagulation state.\r\nAim. To identify the frequency of thromboembolic complications (TEC) in IBD patients and to determine the influence of acquired and inherited hypercoagulation factors that contribute to the development of TE\u0421.\r\nMaterials and methods. The clinical status of 1,238 IBD patients who were treated in 2019 was evaluated. Of these, 748 patients with ulcerative colitis (UC) and 490 patients with Crohn's disease (CD). Among UC patients, there were 369 (49.3%) men and 379 (50.7%) women. In 10.1% of patients with UC, there were clinically significant feasibility studies. There were 227 (46.3%) men and 263 (53.7%) women among patients with CD; 7.3% of patients with CD had clinically significant feasibility studies.\r\nResults. In general 112 (9.0%) of 1,238 IBD patients had clinically significant feasibility studies. Among patients with UC (n=748), 76 (10.2%) showed clinically significant feasibility studies. Among patients with CD (n=490), 36 (7.3%) had a feasibility study. Of 112 IBD patients with clinically significant TEC, 45 (40.2%) had genetic polymorphisms that increase affinity for fibrinogen, increase platelet aggregation, and contribute to a decrease in the activity of folate cycle enzymes, including methylenetetrahydrofolate reductase, which may be manifested by a moderate increase in homocysteine levels. Of the 45 IBD patients with clinically significant TEC due to inherited factors, 30 (66.6%) patients had UC, 15 (33.7%) patients had CD (hazard ratio 1.038, 95% confidence interval 0.7461.444; 2=0.049; p=0.83921); 67 (59.8%) patients with IBD who had clinically significant TEC did not have genetic polymorphisms leading to hypercoagulation.\r\nConclusion. Based on the analysis, we can conclude that such risk factors for the development of TEC as the status of a smoker, long bed rest, taking hormonal contraceptives, varicose veins of the lower extremities, high activity of the disease, glucocorticoids therapy, the extent of intestinal damage in patients with IBD, genetic factors, should be taken into account by gastroenterologists in the treatment of patients with UC and CD. The hereditary factor of hypercoagulation equally affects the development of TEC, both in patients with UC and CD.<\/jats:p>","DOI":"10.26442\/00403660.2022.02.201367","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T13:27:58Z","timestamp":1648646878000},"page":"172-179","source":"Crossref","is-referenced-by-count":4,"title":["Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases"],"prefix":"10.26442","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-2702","authenticated-orcid":false,"given":"Albina A.","family":"Lishchinskaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7250-0977","authenticated-orcid":false,"given":"Oleg V.","family":"Knyazev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-6205","authenticated-orcid":false,"given":"Anna V.","family":"Kagramanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-1067","authenticated-orcid":false,"given":"Galina A.","family":"Dudina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-2041","authenticated-orcid":false,"given":"Elena A.","family":"Sabelnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-7502","authenticated-orcid":false,"given":"Irina A.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-0995","authenticated-orcid":false,"given":"Karina K.","family":"Noskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-7673","authenticated-orcid":false,"given":"Natalia A.","family":"Bodunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-4860","authenticated-orcid":false,"given":"Asfold I.","family":"Parfenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref1","unstructured":"\u0425\u0430\u0442\u044c\u043a\u043e\u0432 \u0418.\u0415., \u041f\u0430\u0440\u0444\u0435\u043d\u043e\u0432 \u0410.\u0418., \u041a\u043d\u044f\u0437\u0435\u0432 \u041e.\u0412., \u0438 \u0434\u0440. \u0412\u043e\u0441\u043f\u0430\u043b\u0438\u0442\u0435\u043b\u044c\u043d\u044b\u0435 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f \u043a\u0438\u0448\u0435\u0447\u043d\u0438\u043a\u0430 \u0432 \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0435 \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0430 \u0438 \u0445\u0438\u0440\u0443\u0440\u0433\u0430. \u041c.: \u0412\u0438\u0442\u0430-\u041f\u0420\u0415\u0421\u0421, 2017 [Khat'kov IE, Parfenov AI, Kniazev OV, et al. Vospalitel'nye zabolevaniia kishechnika v praktike terapevta i khirurga. Moscow: Vita-PRESS, 2017 (in Russian)]."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00943.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2012.07.003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.058"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;35:619-23.","DOI":"10.1080\/003655200750023589"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Sloan WP Jr, Bargen JA, Gage RP. Life histories of patients with chronic ulcerative colitis: A review of 2,000 cases. Gastroenterology. 1950;16:25-38.","DOI":"10.1016\/S0016-5085(19)36591-6"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis III complications. Gut. 1964;5:1-22.","DOI":"10.1136\/gut.5.1.15"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140-5.","DOI":"10.1016\/S0025-6196(12)65200-8"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost. 2001;85:430-4.","DOI":"10.1055\/s-0037-1615600"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12294"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61963-2"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001275"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04026"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0190"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08206.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.42029"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.042"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1076029616632906"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.33878\/2073-7556-2019-18-4-7-36"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;315(8167):514.","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"ref21","unstructured":"\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0435 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435, \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u0438 \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0435 \u0432\u0435\u043d\u043e\u0437\u043d\u044b\u0445 \u0442\u0440\u043e\u043c\u0431\u043e\u044d\u043c\u0431\u043e\u043b\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u043e\u0441\u043b\u043e\u0436\u043d\u0435\u043d\u0438\u0439 (\u0412\u0422\u042d\u041e). \u0424\u043b\u0435\u0431\u043e\u043b\u043e\u0433\u0438\u044f. 2017;4(2):44-6 [Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEO). Phlebology. 2017;4(2):44-6 (in Russian)]."},{"key":"ref22","unstructured":"\u041a\u0443\u0437\u043d\u0435\u0446\u043e\u0432\u0430 \u0411.\u0410. \u041b\u0430\u0431\u043e\u0440\u0430\u0442\u043e\u0440\u043d\u044b\u0435 \u043c\u0435\u0442\u043e\u0434\u044b \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0441\u0438\u0441\u0442\u0435\u043c\u044b \u0441\u0432\u0435\u0440\u0442\u044b\u0432\u0430\u043d\u0438\u044f \u043a\u0440\u043e\u0432\u0438. \u041f\u043e\u0434 \u0440\u0435\u0434. \u0418.\u041d. \u0411\u043e\u043a\u0430\u0440\u0435\u0432\u0430; \u0420\u0410\u0422\u0413\u041f\u0421\u0421 \u0438\u043c. \u0410. \u0428\u043c\u0438\u0434\u0442\u0430. \u041c.: \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0441\u043e\u0446\u0440\u0430\u0437\u0432\u0438\u0442\u0438\u044f \u0420\u0424, 2011 [Kuznetsova BA. Laboratornye metody issledovaniia sistemy svertyvaniia krovi. Pod red. IN Bokareva; RATGPSS im. A. Shmidta. Moscow: Minzdravsotsrazvitiia RF, 2011 (in Russian)]."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"C\u0442\u043e\u043c\u0435\u043d\u0441\u043a\u0430\u044f \u0418.\u0421., \u041a\u043e\u0441\u0442\u0440\u043e\u0432\u0430 \u041e.\u042e., \u0421\u0442\u0440\u0443\u0447\u043a\u043e \u0413.\u042e., \u0422\u0438\u043c\u043e\u0444\u0435\u0435\u0432\u0430 \u041d.\u042e. \u0422\u0440\u043e\u043c\u0431\u043e\u044d\u043b\u0430\u0441\u0442\u043e\u043c\u0435\u0442\u0440\u0438\u044f \u2013 \u043c\u0435\u0442\u043e\u0434 \u043b\u0430\u0431\u043e\u0440\u0430\u0442\u043e\u0440\u043d\u043e\u0439 \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0438 \u043d\u0430\u0440\u0443\u0448\u0435\u043d\u0438\u0439 \u0441\u0438\u0441\u0442\u0435\u043c\u044b \u0433\u0435\u043c\u043e\u0441\u0442\u0430\u0437\u0430. \u041c\u0435\u0434. \u0430\u043b\u044c\u043c\u0430\u043d\u0430\u0445. 2017;2:96-8 [Stomenskaia IS, Kostrova OIu, Struchko GIu, Timofeeva NIu. Thromboelastometry is a method. I.S. Stomenskaya, et al. Medical Almanac. 2017;2:96-8 (in Russian)].","DOI":"10.21145\/2499-9954-2017-2-96-98"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i17.4857"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.195558"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789776-84"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619-23.","DOI":"10.1056\/NEJM199603073341002"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18:555-9.","DOI":"10.1089\/jir.1998.18.555"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008173430702"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Chiarantini E, Valanzano R, Liotta AA. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 1996;82:137-46.","DOI":"10.1016\/0049-3848(96)00060-6"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995;7:1183-8.","DOI":"10.1097\/00042737-199512000-00010"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res. 1999;19:757-60.","DOI":"10.1089\/107999099313604"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn\u2019s disease. Gastroenterology. 1999;117:58-64.","DOI":"10.1016\/S0016-5085(99)70550-0"},{"key":"ref34","unstructured":"Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations \u2013 United States, 2007\u20132009. MMWR Morb Mortal Wkly Rep. 2012;61:401-4."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz269;"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/apt.1229"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.15720241.2008.02052.x"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/105511\/79929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/105511\/79929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T13:29:03Z","timestamp":1648646943000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/105511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2022.02.201367","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}